|
|
|
 |
|
Radiofrequency ablation of lung tumours |
|
|
Riccardo Lencioni
University of Pisa, Pisa, Italy
Address for correspondence:
Università di Pisa, Dipartimento di Oncologia,
dei Trapianti e delle Nuove Tecnologie
in Medicina, Divisione di Radiologia
Diagnostica e Interventistica, Via Roma,
67 – 56126 Pisa, Italy
Tel: +39 (050) 992509
Email: lencioni@do.med.unipi.it
Introduction
Image-guided percutaneous radiofrequency (RF) ablation
is a minimally invasive technique for the treatment of
solid tumours that has been introduced into clinical
practice relatively recently. It is now considered a
feasible treatment option for patients with primary
hepatocellular cancer or limited liver metastases.
As the technology evolves, RF ablation is now being
evaluated in other types of tumours. A general review
of RF ablation was included in a previous issue of C2I2.
This paper focuses on the use of the technique for lung
tumours and updates an earlier review1 with new clinical
trial results presented at the Annual Scientific Meeting
of the Cardiovascular and Interventional Radiology
Society of Europe (CIRSE) in September 2005.
The lung is the most common site for primary cancer
worldwide (accounting for 13% of all new cancer cases
in the US), and is also a common site for metastatic
disease. Many of these patients are not suitable for
surgical treatment, often because of their age, poor
cardiovascular or respiratory function, or other serious
coexisting health conditions or because of the size and
location of the tumour. Hence, it is logical to extend the
use of RF ablation to patients with limited lung tumours
not eligible for surgical resection.
Full text >>
|
|
|
